Partial Breast Radiotherapy in Low-risk Breast cancer group using a stereotactic MR-guided adaptive approach; a phase II study - PARLOB

Vrije Universiteit Medisch Centrum0 个研究点目标入组 50 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

暂无简介。

•- Age > 50 years
•- WHO performance score 0-2
•- Pathology proven breast cancer with following histology: invasive ductal carcinoma, mucinous, tubular, medullary, colloid cc, and associated LCIS
•- Any histologic grade
•- Any hormonal receptor status
•- T-stage: Tumor size * 3cm (pT1-2)
•- N-stage: No positive lymph nodes examined by sentinel lymph node biopsy or axillary lymph node dissection (at least 6 nodes pathologically examined)
•- Radical resection of tumor with * 2mm surgical margin free of tumour
•- All patients should be able to undergo MRI scans
•- Ability to provide written informed consent.
•- Ability to perform breath-hold for at least 17 seconds

•- Breast cancer histology of invasive lobular carcinoma, ductal carcinoma in situ sec
•- Breast cancer with a multicentric or multifocality character
•- An extensive intraductal component in pathology examination
•- Lympho-vascular invasion in the pathology examination
•- Treatment with neoadjuvant chemotherapy before lumpectomy
•- Breast conserving surgery with an oncoplastic breast surgery technique
•- Re-excision of tumour in ipsilateral breast
•- Open surgical wound or wound infection
•- Previous irradiation in the ipsilateral breast
•- Contra-indications for MRI

发起方